{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T21:11:09Z","timestamp":1778015469305,"version":"3.51.4"},"reference-count":159,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01128","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:50:50Z","timestamp":1591332650000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma"],"prefix":"10.3389","volume":"11","author":[{"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Sierro-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1179\/1024533214Z.000000000333","article-title":"Multiple myeloma","volume":"20","author":"Mehta","year":"2015","journal-title":"Hematology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.beha.2018.03.002","article-title":"CARs and other T cell therapies for MM: the clinical experience","volume":"31","author":"Danhof","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0145-212600093-X","article-title":"Human CD38: A (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: a target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B22","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (Syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O'Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1182\/blood-2017-01-761643","article-title":"CD138 mediates selection of mature plasma cells by regulating their survival","volume":"129","author":"Mccarron","year":"2017","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int J Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI insight"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell Therapy for Relapsed\/Refractory Multiple Myeloma: Initial Proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical Responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2019-129562","article-title":"Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME)","volume":"134","author":"Costello","year":"2019","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti bcma CAR T therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2019-126660","article-title":"Updated results from an ongoing phase 1 clinical study of bb21217 anti-bcma CAR T Cell therapy","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10428190290012146","article-title":"CD19 expression and growth inhibition of tumours in human multiple myeloma","volume":"43","author":"Ishikawa","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1126\/science.1373518","article-title":"CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes","volume":"256","author":"Carter","year":"1992","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.cell.2017.12.002","article-title":"CD19 CAR T Cells","volume":"171","author":"Sadelain","year":"2017","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.clml.2019.09.277","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'connor","year":"2004","journal-title":"J Exp Med J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor t cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1200\/JCO.2019.37.15_suppl.8007","article-title":"Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R\/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) phase I dose escalation study","volume":"37","author":"Topp","year":"2019","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-204530576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma: a dose-escalation and expansion phase 1 trial (BMA117159) HHS public access","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-cell therapy in multiple myeloma : can we do better?","volume":"34","author":"Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1182\/blood-2018-99-111576","article-title":"Improved expansion and function of CAR T Cell products from cultures initiated at defined CD4:CD8 ratios","volume":"132","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.semcancer.2019.11.004","article-title":"Determinants of response and resistance to CAR T cell therapy","volume":"24","author":"Lesch","year":"2019","journal-title":"Semin Cancer Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.3390\/ijms20205010","article-title":"Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies","author":"Song","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-bcma car t cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood.V130.Suppl_1.505.505","article-title":"Safety and efficacy of B-Cell Maturation Antigen (BCMA)-Specific chimeric antigen receptor T Cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM)","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"24","author":"Lee","year":"2014","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1200\/EDBK_200889","article-title":"CAR T Cells and Other Cellular Therapies for Multiple Myeloma:2018 Update","volume":"38","author":"Cohen","year":"2018","journal-title":"Am Soc Clin Oncol Educ B"},{"key":"B66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","article-title":"Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes","volume":"103","author":"Lanza","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B68","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.4049\/jimmunol.151.8.4081","article-title":"Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor","volume":"151","author":"Paliogianni","year":"1993","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0197349","article-title":"Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design","volume":"13","author":"Drent","year":"2018","journal-title":"PLoS ONE"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: The CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1042\/BST20160037","article-title":"Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells - A completed study overview","volume":"44","author":"Lamers","year":"2016","journal-title":"Biochem Soc Trans."},{"key":"B74","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/00005392-199511000-00004","article-title":"High Expression of a CD38-Like Molecule in Normal Prostatic Epithelium and its Differential Loss in Benign and Malignant Disease","volume":"154","author":"Kramer","year":"1995","journal-title":"J Urol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"50791","DOI":"10.1074\/jbc.M308034200","article-title":"CD38 Signaling in T Cells Is Initiated within a Subset of Membrane Rafts Containing Lck and the CD3-\u03b6 Subunit of the T Cell Antigen Receptor","volume":"278","author":"Mu\u00f1oz","year":"2003","journal-title":"J Biol Chem"},{"key":"B79","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/cncr.31243","article-title":"Current developments in immunotherapy in the treatment of multiple myeloma","volume":"124","author":"K\u00f6hler","year":"2018","journal-title":"Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41591-018-0212-6","article-title":"Tumors evading CARs-the chase is on","volume":"24","author":"Rafiq","year":"2018","journal-title":"Nat Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from car t-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the btk inhibitor ibrutinib to anti-cd19 chimeric antigen receptor T Cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood."},{"key":"B89","doi-asserted-by":"publisher","first-page":"956304","DOI":"10.1155\/2010\/956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Bachmann","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2141.2010.08203.x","article-title":"CD138 shedding in plasma cell myeloma","volume":"150","author":"Grigoriadis","year":"2010","journal-title":"Br J Haematol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"G-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/trf.15287","article-title":"Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics","volume":"59","author":"Elavia","year":"2019","journal-title":"Transfusion."},{"key":"B95","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1073\/pnas.1714478115","article-title":"Thymic involution and rising disease incidence with age","volume":"115","author":"Palmer","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B97","first-page":"595","article-title":"T cell ageing: Effects of age on development, survival & function","volume":"138","author":"Salam","year":"2013","journal-title":"Indian J Med Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2018","journal-title":"Front Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Van Der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov."},{"key":"B102","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The Pharmacology of T Cell Therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B103","doi-asserted-by":"publisher","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"e1271857","DOI":"10.1080\/2162402X.2016.1271857","article-title":"Steering CAR T cells to distinguish friend from foe","volume":"8","author":"Caruso","year":"2019","journal-title":"Oncoimmunology."},{"key":"B112","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","article-title":"Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D","volume":"1518","author":"Br\u00e4uner-Osborne","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"B113","doi-asserted-by":"publisher","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"B114","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.4049\/jimmunol.1003650","article-title":"Strength of TCR-Peptide\/MHC interactions and in vivo T cell responses","volume":"186","author":"Corse","year":"2011","journal-title":"J Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/cei.12570","article-title":"T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells","volume":"180","author":"Tan","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Mol Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41467-018-02912-x","article-title":"Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression","volume":"9","author":"Han","year":"2018","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/ijms21010204","article-title":"The evolving protein engineering in the design of chimeric antigen receptor T cells","volume":"21","author":"Hughes-Parry","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B120","doi-asserted-by":"publisher","first-page":"21533","DOI":"10.18632\/oncotarget.4071","article-title":"A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget"},{"key":"B121","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","article-title":"Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo","volume":"1","author":"Lanitis","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule\u00e2\u20ac\u201cgated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B124","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision Tumor Recognition by T Cells with Combinatorial Antigen-Sensing Circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B125","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-019-0823-5","article-title":"Chimeric antigen receptor T cell therapies for multiple myeloma","volume":"12","author":"Wu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-019-1092-1","article-title":"Recent updates on CAR T clinical trials for multiple myeloma","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1182\/blood-2019-129740","article-title":"Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study","volume":"134","author":"Yan","year":"2019","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1074\/jbc.M411714200","article-title":"Structures of APRIL-receptor complexes: Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding","volume":"280","author":"Hymowitz","year":"2005","journal-title":"J Biol Chem"},{"key":"B131","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1074\/jbc.M312316200","article-title":"Engineering an APRIL-specific B Cell Maturation Antigen","volume":"279","author":"Patel","year":"2004","journal-title":"J Biol Chem"},{"key":"B132","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","article-title":"Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Popat","year":"2019","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric April-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"key":"B136","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood-2019-126145","article-title":"Optimal dual-targeted CAR construct simultaneously targeting bcma and GPRC5D prevents Bcma-escape driven relapse in multiple myeloma","volume":"134","author":"Fernandez de Larrea","year":"2019","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature01543","article-title":"Ligand-receptor binding revealed by the TNF family member TALL-1","volume":"423","author":"Liu","year":"2003","journal-title":"Nature"},{"key":"B138","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"B139","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","article-title":"Role of memory T cell subsets for adoptive immunotherapy","volume":"28","author":"Busch","year":"2016","journal-title":"Semin Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","article-title":"Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kd inhibitors and VIP antagonists","volume":"2","author":"Petersen","year":"2018","journal-title":"Blood Adv"},{"key":"B142","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD81 memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood."},{"key":"B143","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Philip","year":"2015","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long Terminal Repeat CRISPR-CAR-Coupled \u201cUniversal\u201d T Cells Mediate Potent Anti-leukemic Effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol Ther"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/mt.2015.104","article-title":"A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and Design of Chimeric Antigen Receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol Ther"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/febs.13586","article-title":"Potential pitfalls of CRISPR\/Cas9-mediated genome editing","volume":"283","author":"Peng","year":"2016","journal-title":"FEBS J"},{"key":"B152","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fimmu.2019.00456","article-title":"Building potent chimeric antigen receptor T cells with CRISPR genome editing","volume":"10","author":"Liu","year":"2019","journal-title":"Front Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B154","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"B157","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"B158","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-Tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B159","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","article-title":"CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment","volume":"79","author":"Mollanoori","year":"2018","journal-title":"Hum Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T23:34:59Z","timestamp":1696203299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":159,"alternative-id":["10.3389\/fimmu.2020.01128"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01128","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"article-number":"1128"}}